Trial Profile
Pilot Study of Iodine-124 Labeled Chimeric G250 (124I-cG250) in Presurgical Patients With Renal Masses
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Girentuximab I-124 (Primary)
- Indications Renal cancer
- Focus Diagnostic use
- 20 Jun 2014 New trial record